Back to results

CompletedPhase 3

Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity

NCT00459771

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Jeroen Bosch Hospital

's-Hertogenbosch, Netherlands

+18 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2007-06
Enrollment: 210 participants
Sponsor: The Netherlands Cancer Institute
Purpose: treatment

Locations (19)

Jeroen Bosch Hospital's-Hertogenbosch, Netherlands
Medisch Centrum AlkmaarAlkmaar, Netherlands
FlevoziekenhuisAlmere Stad, Netherlands
The Netherlands Cancer InstituteAmsterdam, Netherlands
Onze Lieve Vrouwe GasthuisAmsterdam, Netherlands
Slotervaart HospitalAmsterdam, Netherlands
Wilhelmina ZiekenhuisAssen, Netherlands
Deventer ZiekenhuisDeventer, Netherlands
Medisch Spectrum TwenteEnschede, Netherlands
Martini ZiekenhuisGroningen, Netherlands
University Medical Center GroningenGroningen, Netherlands
Ziekenhuis de TjongerschansHeerenveen, Netherlands
Medisch Centrum LeeuwardenLeeuwarden, Netherlands
Antonius ZiekenhuisNieuwegein, Netherlands
Canisius-Wilhelmina HospitalNijmegen, Netherlands
UMC St. RadboudNijmegen, Netherlands
VieCuri Medisch Centrum voor Noord-LimburgVenlo, Netherlands
Streekziekenhuis Koningin BeatrixWinterswijk, Netherlands
Isala KliniekenZwolle, Netherlands

Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity — TrialFind